Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 18

1.

Towards Inhibition of Vif-APOBEC3G Interaction: Which Protein to Target?

Cadima-Couto I, Goncalves J.

Adv Virol. 2010;2010:649315. doi: 10.1155/2010/649315. Epub 2010 Sep 21.

2.

HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Cadima-Couto I, Saraiva N, Santos AC, Goncalves J.

J Neuroimmune Pharmacol. 2011 Jun;6(2):296-307. doi: 10.1007/s11481-011-9258-7. Epub 2011 Jan 29.

PMID:
21279453
3.

Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.

Walker RC Jr, Khan MA, Kao S, Goila-Gaur R, Miyagi E, Strebel K.

J Virol. 2010 May;84(10):5201-11. doi: 10.1128/JVI.02318-09. Epub 2010 Mar 10.

4.

Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Hultquist JF, Harris RS.

Future Virol. 2009 Nov 1;4(6):605.

5.

Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.

Albin JS, Harris RS.

Expert Rev Mol Med. 2010 Jan 22;12:e4. doi: 10.1017/S1462399409001343. Review.

6.

Host restriction of HIV-1 by APOBEC3 and viral evasion through Vif.

Niewiadomska AM, Yu XF.

Curr Top Microbiol Immunol. 2009;339:1-25. doi: 10.1007/978-3-642-02175-6_1. Review.

PMID:
20012521
7.

A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.

Zhen A, Wang T, Zhao K, Xiong Y, Yu XF.

J Virol. 2010 Feb;84(4):1902-11. doi: 10.1128/JVI.01509-09. Epub 2009 Nov 25.

8.

Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.

Smith JL, Bu W, Burdick RC, Pathak VK.

Trends Pharmacol Sci. 2009 Dec;30(12):638-46. doi: 10.1016/j.tips.2009.09.006. Review.

9.

Interactions in vivo between the Vif protein of HIV-1 and the precursor (Pr55(GAG)) of the virion nucleocapsid proteins.

Syed F, McCrae MA.

Arch Virol. 2009;154(11):1797-805. doi: 10.1007/s00705-009-0520-8. Epub 2009 Oct 14.

PMID:
19826902
10.

Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif.

Romani B, Engelbrecht S, Glashoff RH.

Arch Virol. 2009;154(10):1579-88. doi: 10.1007/s00705-009-0481-y. Epub 2009 Aug 12. Review.

PMID:
19669862
11.

Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.

Henriet S, Mercenne G, Bernacchi S, Paillart JC, Marquet R.

Microbiol Mol Biol Rev. 2009 Jun;73(2):211-32. doi: 10.1128/MMBR.00040-08. Review.

12.

Accessories to the crime: recent advances in HIV accessory protein biology.

Gramberg T, Sunseri N, Landau NR.

Curr HIV/AIDS Rep. 2009 Feb;6(1):36-42. Review.

13.

APOBEC proteins and intrinsic resistance to HIV-1 infection.

Malim MH.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):675-87. doi: 10.1098/rstb.2008.0185. Review.

14.

Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.

Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK.

J Virol. 2009 Feb;83(4):1992-2003. doi: 10.1128/JVI.01621-08. Epub 2008 Nov 26.

15.

APOBEC3G: an intracellular centurion.

Chiu YL, Greene WC.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):689-703. doi: 10.1098/rstb.2008.0193. Review.

16.

Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.

He Z, Zhang W, Chen G, Xu R, Yu XF.

J Mol Biol. 2008 Sep 12;381(4):1000-11. doi: 10.1016/j.jmb.2008.06.061. Epub 2008 Jun 28.

PMID:
18619467
17.

Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.

Mehle A, Wilson H, Zhang C, Brazier AJ, McPike M, Pery E, Gabuzda D.

J Virol. 2007 Dec;81(23):13235-41. Epub 2007 Sep 26.

Supplemental Content

Support Center